{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Parkinson Disease",
            "NStudiesAvail": 430108,
            "NStudiesFound": 16,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 16,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Hoehn and Yahr (H-Y) staging was used to determine the stage of PD based on clinical findings and functional disability. In H-Y staging is a rating scale measured in an ordinal level.",
                              "The MMSE was used to measure cognition. This test consists of 2 parts: language and performance. Its total score can range from 0 to 30, with a higher score indicating better function.",
                              "The HAMD 24 is used to assessed the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. There are 24 items in the HAMD 24.",
                              "The HAMA-14 is used to assessed the anxiety symptoms. Its total score can range from 0 to 56. Lower score represents a better outcome.",
                              "Adverse reaction including temperature changes,the change of blood pressure,allergy and so on."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of in the Hoehn and Yahr staging",
                              "Changes of the Mini-Mental State Examination (MMSE)",
                              "Changes of the Hamilton depression scales 24 (HAMD 24)",
                              "Changes of the Hamilton Anxiety Scale 14 (HAMA-14)",
                              "Adverse reaction"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months",
                              "Post cell transplantation: 1, 3, 6, 12months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03550183"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assessed by Unified Parkinson's Disease Rating Scale (UPDRS).",
                              "Assessed by UPDRS",
                              "Assessed by UPDRS",
                              "Assessed by UPDRS"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Effect assessment",
                              "Effect assessment",
                              "Effect assessment",
                              "Effect assessment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 month after transplantation",
                              "3 months after transplantation",
                              "6 months after transplantation",
                              "12 months after transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01446614"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The UPDRS serves as a disability and impairment scale for progression follow-up and is divided into four sections.\n\nPart I: evaluation of mentation, behavior, and mood (13 questions).\nPart II: evaluation of activities of daily living including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food (13 questions).\nPart III: motor examination (33 scores based on 18 questions with right, left or other body distributions scores)\nPart IV: motor complications (6 questions)\n\nAll items have 5 response options with uniform anchors of: 0 = normal, 1 = slight (symptoms/signs with sufficiently low frequency or intensity to cause no impact on function), 2 = mild (symptoms/signs of frequency or intensity sufficient to cause a modest impact on function, 3 = moderate (symptoms/signs sufficiently frequent or intense to impact considerably, but not prevent function), 4 = severe (symptoms/signs that prevent function).",
                              "The UPDRS serves as a disability and impairment scale for progression follow-up and is divided into four sections.\n\nPart I: evaluation of mentation, behavior, and mood (13 questions).\nPart II: evaluation of activities of daily living including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food (13 questions).\nPart III: motor examination (33 scores based on 18 questions with right, left or other body distributions scores)\nPart IV: motor complications (6 questions)\n\nAll items have 5 response options with uniform anchors of: 0 = normal, 1 = slight (symptoms/signs with sufficiently low frequency or intensity to cause no impact on function), 2 = mild (symptoms/signs of frequency or intensity sufficient to cause a modest impact on function, 3 = moderate (symptoms/signs sufficiently frequent or intense to impact considerably, but not prevent function), 4 = severe (symptoms/signs that prevent function).",
                              "The UPDRS serves as a disability and impairment scale for progression follow-up and is divided into four sections.\n\nPart I: evaluation of mentation, behavior, and mood (13 questions).\nPart II: evaluation of activities of daily living including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food (13 questions).\nPart III: motor examination (33 scores based on 18 questions with right, left or other body distributions scores)\nPart IV: motor complications (6 questions)\n\nAll items have 5 response options with uniform anchors of: 0 = normal, 1 = slight (symptoms/signs with sufficiently low frequency or intensity to cause no impact on function), 2 = mild (symptoms/signs of frequency or intensity sufficient to cause a modest impact on function, 3 = moderate (symptoms/signs sufficiently frequent or intense to impact considerably, but not prevent function), 4 = severe (symptoms/signs that prevent function).",
                              "The UPDRS serves as a disability and impairment scale for progression follow-up and is divided into four sections.\n\nPart I: evaluation of mentation, behavior, and mood (13 questions).\nPart II: evaluation of activities of daily living including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food (13 questions).\nPart III: motor examination (33 scores based on 18 questions with right, left or other body distributions scores)\nPart IV: motor complications (6 questions)\n\nAll items have 5 response options with uniform anchors of: 0 = normal, 1 = slight (symptoms/signs with sufficiently low frequency or intensity to cause no impact on function), 2 = mild (symptoms/signs of frequency or intensity sufficient to cause a modest impact on function, 3 = moderate (symptoms/signs sufficiently frequent or intense to impact considerably, but not prevent function), 4 = severe (symptoms/signs that prevent function).",
                              "Parts III and IV of the UPDRS will be performed as described above.",
                              "Parts III and IV of the UPDRS will be performed as described above.",
                              "Parts III and IV of the UPDRS will be performed as described above.",
                              "Parts III and IV of the UPDRS will be performed as described above.",
                              "Time in seconds required to stand from a chair, walk 7meters, turn, walk back to the chair and sit down.",
                              "Time in seconds required to stand from a chair, walk 7meters, turn, walk back to the chair and sit down.",
                              "Time in seconds required to stand from a chair, walk 7meters, turn, walk back to the chair and sit down.",
                              "Time in seconds required to stand from a chair, walk 7meters, turn, walk back to the chair and sit down.",
                              "The Modified Hoehn and Yahr Scale is a staging instrument that defines broad categories of motor function in Parkinson's disease, starting at Stage 0: no signs of disease to the highest stage 5: wheelchair bound or bedridden unless aided.",
                              "The Modified Hoehn and Yahr Scale is a staging instrument that defines broad categories of motor function in Parkinson's disease, starting at Stage 0: no signs of disease to the highest stage 5: wheelchair bound or bedridden unless aided.",
                              "The Modified Hoehn and Yahr Scale is a staging instrument that defines broad categories of motor function in Parkinson's disease, starting at Stage 0: no signs of disease to the highest stage 5: wheelchair bound or bedridden unless aided.",
                              "The Modified Hoehn and Yahr Scale is a staging instrument that defines broad categories of motor function in Parkinson's disease, starting at Stage 0: no signs of disease to the highest stage 5: wheelchair bound or bedridden unless aided.",
                              "Diffusion tensor and T2 imaging with the resting state functional connectivity technique will be used.",
                              "Resting cerebral blood flow (CBF) will be measured using a pseudo-continuous arterial spin labeling (pCASL) MRI sequence with gradient-echo echo-planar imaging (EPI), which allows for a non-invasive quantification of CBF.",
                              "A set of diffusion-weighted image volumes (32-directions, high angular resolution) will be collected using the gradient overplus option with one B0 (non-diffusion weighted) image volume acquired before the acquisition of one repetition of the diffusion-weighted scans. Diffusion tensor and associated computations will be performed. White matter microstructure will be examined, which represents the structural pathways linking specific cortical and subcortical regions. It will be determined whether there is increased fractional anisotropy and decreased mean diffusivity along white matter fibers that link regions exhibiting increased functional connectivity, such as substantia nigra and dorsal striatum.",
                              "Anatomical imaging allows visualization of the brain structure at the level of about 1 cubic millimeter. These scans will be used to estimate the volume of subcortical structures (e.g., putamen, caudate nucleus).",
                              "Anatomical imaging allows visualization of the brain structure at the level of about 1 cubic millimeter. These scans will be used to measure cortical thickness (e.g., gray matter density).",
                              "Anatomical imaging allows visualization of the brain structure at the level of about 1 cubic millimeter. These scans will be used to detect any gross structural changes or inflammation that appear during the course of treatment.",
                              "Whole-brain echo-planar imaging (EPI) runs sensitive to BOLD contrast will be acquired while participants do self-paced finger tapping using their left and right hands at separate points in time, and during the resting state after being instructed to remain still and fixate on a white crosshair displayed on a black background during the functional acquisition. Functional imaging will be done in the OFF medication state. It will be determined whether there is a reduction in the abnormally high activity pattern in motor cortex and an increase in putamen activity.",
                              "The Schwab & England scale is a physician assessment of the subject's level of independence. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson disease appeared. Scores range from 100% to 0% in increments of 10%, where 100% is completely independent and 0% is only vegetative functions.",
                              "The Schwab & England scale is a physician assessment of the subject's level of independence. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson disease appeared. Scores range from 100% to 0% in increments of 10%, where 100% is completely independent and 0% is only vegetative functions.",
                              "The Schwab & England scale is a physician assessment of the subject's level of independence. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson disease appeared. Scores range from 100% to 0% in increments of 10%, where 100% is completely independent and 0% is only vegetative functions.",
                              "The Schwab & England scale is a physician assessment of the subject's level of independence. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson disease appeared. Scores range from 100% to 0% in increments of 10%, where 100% is completely independent and 0% is only vegetative functions.",
                              "The PDQ-39 is a 39 questions Parkinson's Disease self-completed questionnaire that comprises 8 domains: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items). All items are assumed to impact QoL and must be answered to compute scores for each dimension. Questions are answered based on experiences from the preceding month using a 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each scores range from 0 = never have difficulty to 100 = always have difficulty.",
                              "The PDQ-39 is a 39 questions Parkinson's Disease self-completed questionnaire that comprises 8 domains: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items). All items are assumed to impact QoL and must be answered to compute scores for each dimension. Questions are answered based on experiences from the preceding month using a 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each scores range from 0 = never have difficulty to 100 = always have difficulty.",
                              "The PDQ-39 is a 39 questions Parkinson's Disease self-completed questionnaire that comprises 8 domains: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items). All items are assumed to impact QoL and must be answered to compute scores for each dimension. Questions are answered based on experiences from the preceding month using a 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each scores range from 0 = never have difficulty to 100 = always have difficulty.",
                              "The PDQ-39 is a 39 questions Parkinson's Disease self-completed questionnaire that comprises 8 domains: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items). All items are assumed to impact QoL and must be answered to compute scores for each dimension. Questions are answered based on experiences from the preceding month using a 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each scores range from 0 = never have difficulty to 100 = always have difficulty.",
                              "The Montreal Cognitive Assessment is a rapid screening instrument for working memory, visual-spatial abilities, executive function, attention, concentration, language and orientation. The total score ranges from 0 to 30; a score of 26 or above is considered normal.",
                              "Investigators will assess cytokines associated with inflammation [interleukin-6 (IL-6), Interleukin-1 beta (IL-1\u03b2), Tumor Necrosis Factor beta (TNF\u03b2)]; cell growth and differentiation [Brain-derived neurotrophic factor (BDNF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)]; monocyte migration [Fractalkine, Eotaxin, monocyte chemotactic protein 1 (MCP-1), Macrophage Inflammatory Protein 1 beta (MIP-1\u03b2)]; and adaptive immune response [interleukin 12 subunit beta (IL-12p40), interleukin 7 (IL-7), interleukin 9 (IL-9), interleukin 4 (IL-4)] will be measured.",
                              "Investigators will assess cytokines associated with inflammation [interleukin-6 (IL-6), Interleukin-1 beta (IL-1\u03b2), Tumor Necrosis Factor beta (TNF\u03b2)]; cell growth and differentiation [Brain-derived neurotrophic factor (BDNF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)]; monocyte migration [Fractalkine, Eotaxin, monocyte chemotactic protein 1 (MCP-1), Macrophage Inflammatory Protein 1 beta (MIP-1\u03b2)]; and adaptive immune response [interleukin 12 subunit beta (IL-12p40), interleukin 7 (IL-7), interleukin 9 (IL-9), interleukin 4 (IL-4)] will be measured.",
                              "Investigators will assess cytokines associated with inflammation [interleukin-6 (IL-6), Interleukin-1 beta (IL-1\u03b2), Tumor Necrosis Factor beta (TNF\u03b2)]; cell growth and differentiation [Brain-derived neurotrophic factor (BDNF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)]; monocyte migration [Fractalkine, Eotaxin, monocyte chemotactic protein 1 (MCP-1), Macrophage Inflammatory Protein 1 beta (MIP-1\u03b2)]; and adaptive immune response [interleukin 12 subunit beta (IL-12p40), interleukin 7 (IL-7), interleukin 9 (IL-9), interleukin 4 (IL-4)] will be measured.",
                              "Investigators will assess cytokines associated with inflammation [interleukin-6 (IL-6), Interleukin-1 beta (IL-1\u03b2), Tumor Necrosis Factor beta (TNF\u03b2)]; cell growth and differentiation [Brain-derived neurotrophic factor (BDNF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)]; monocyte migration [Fractalkine, Eotaxin, monocyte chemotactic protein 1 (MCP-1), Macrophage Inflammatory Protein 1 beta (MIP-1\u03b2)]; and adaptive immune response [interleukin 12 subunit beta (IL-12p40), interleukin 7 (IL-7), interleukin 9 (IL-9), interleukin 4 (IL-4)] will be measured.",
                              "The CSSRS rating scale is a set of questions directed towards eliciting verbalization of suicidal feelings or actions"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score",
                              "Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score",
                              "Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score",
                              "Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score",
                              "Change in motor function as assessed by the UPDRS Motor score",
                              "Change in motor function as assessed by the UPDRS Motor score",
                              "Change in motor function as assessed by the UPDRS Motor score",
                              "Change in motor function as assessed by the UPDRS Motor score",
                              "Change in motor function as assessed by Timed-Up-and-Go (TUG)",
                              "Change in motor function as assessed by Timed-Up-and-Go (TUG)",
                              "Change in motor function as assessed by Timed-Up-and-Go (TUG)",
                              "Change in motor function as assessed by Timed-Up-and-Go (TUG)",
                              "Change in disability as measured by the Modified Hoehn and Yahr Scale",
                              "Change in disability as measured by the Modified Hoehn and Yahr Scale",
                              "Change in disability as measured by the Modified Hoehn and Yahr Scale",
                              "Change in disability as measured by the Modified Hoehn and Yahr Scale",
                              "functional connectivity between substantia nigra and dorsal striatum as assessed by resting state functional magnetic resonance imaging (fMRI)",
                              "perfusion as assessed by arterial spin-labeled (ASL) perfusion MRI",
                              "structural connectivity as assessed by diffusion-weighted MRI for diffusion tensor image (DTI) analysis",
                              "volume of subcortical structures as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery",
                              "cortical thickness as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery",
                              "Change in gross brain structure as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery",
                              "Change in brain activity as assessed by task state fMRI",
                              "Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score",
                              "Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score",
                              "Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score",
                              "Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score",
                              "Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)",
                              "Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)",
                              "Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)",
                              "Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)",
                              "Change in cognitive function as assessed by the Montreal Cognitive Assessment (MoCA)",
                              "Change in immunologic response as assessed by plasma concentrations of cytokines",
                              "Change in immunologic response as assessed by plasma concentrations of cytokines",
                              "Change in immunologic response as assessed by plasma concentrations of cytokines",
                              "Change in immunologic response as assessed by plasma concentrations of cytokines",
                              "Change in suicidal ideation or behaviors as assessed by and Columbia Suicide Severity Rating Scale (CSSRS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 3 weeks",
                              "baseline, 12 weeks",
                              "baseline, 24 weeks",
                              "baseline, 52 weeks",
                              "baseline, 3 weeks",
                              "baseline, 12 weeks",
                              "baseline, 24 weeks",
                              "baseline, 52 weeks",
                              "baseline, 3 weeks",
                              "baseline, 12 weeks",
                              "baseline, 24 weeks",
                              "baseline, 52 weeks",
                              "baseline, 3 weeks",
                              "baseline, 12 weeks",
                              "baseline, 24 weeks",
                              "baseline, 52 weeks",
                              "baseline",
                              "baseline",
                              "baseline",
                              "baseline",
                              "baseline",
                              "baseline",
                              "baseline",
                              "baseline, 3 weeks",
                              "baseline, 12 weeks",
                              "baseline, 24 weeks",
                              "baseline, 52 weeks",
                              "baseline, 3 weeks",
                              "baseline, 12 weeks",
                              "baseline, 24 weeks",
                              "baseline, 52 weeks",
                              "baseline, 52 weeks",
                              "baseline, 3 weeks",
                              "baseline, 12 weeks",
                              "baseline, 24 weeks",
                              "baseline, 52 weeks",
                              "Screening, 3 weeks, 12 weeks, 24 weeks, 52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02611167"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05152394"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Donor specific antibodies (DSA) in serum of patients will be measured and compared to baseline to determine if there is a development of antibody response to donor HLA (human leukocyte antigen). This will determine if there is a possibility of anti-donor alloimmune response after the first or second infusion of MSC, which might lead to a subsequent antibody-mediated rejection (AMR) with the following infusion. Testing will be done at the these time points to determine if 2nd or 3rd infusions will continue.",
                              "This test uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. A longer duration of time indicates a worse outcome",
                              "The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool that evaluates suicidal ideation and behavior. It rates an individual's degree of suicidal ideation on a scale, ranging from \"wish to be dead\" to \"active suicidal ideation with specific plan and intent\". Exclusionary criteria views 1 or more positive answers in the last month as not eligible for participation. In follow up, one positive response requires further investigation.",
                              "The Geriatric Depression Scale Short form (GDS-SF) is a 15-item screening tool that is used to identify depression in older adults. Answers indicating depression are in bold and italicized; score one point for each bold one selected. A score of 0 to 5 is normal. A score greater than 5 suggests depression and requires evaluation, whereas a score of 10 or greater would require evaluation for treatment .",
                              "Examples of these are IL-1beta, IL-6, TNF-alpha, COX-2 and PGE-2. These are measured by Magnetic Bead Panel - Multiplex Assay or ELISA, allowing for specificity in the blood.",
                              "Examples of these are CCL2 (MCP-1), CCL7 (MCP-3), CCL11 (Eotaxin) CCL2 (MDC), CXCL10 (IP-10), CX3CL1 (Fractalkine). These will be measured by Magnetic Bead Panel - Multiplex Assay or ELISA, allowing for specificity in the blood.",
                              "Examples of these are Glial Derived Neurotrophic Factor, Brain Derived Neurotrophic Factor and Vascular Epidermal Growth Factor . These will be measured by ELISA specific to blood and CSF.",
                              "Examples of these are homovanillic acid and 5-hydroxytryptamine. These will be measured in CSF and blood by ELISA."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety and tolerability as measured by serious adverse reactions.",
                              "Safety and tolerability as measured by immunologic responses.",
                              "Motor function as measured by the Timed-Up-and-Go (TUG) scale",
                              "Global measurement of disability as measured by the change in the screening \"Off\" modified Hoehn and Yahr (H&Y)",
                              "Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)",
                              "Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)",
                              "Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)",
                              "Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).",
                              "Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)",
                              "Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)",
                              "Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)",
                              "Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)",
                              "Measurement of putative paracrine mechanism of MSCs using neuroimaging",
                              "Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.",
                              "Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.",
                              "Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors",
                              "Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters",
                              "Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)",
                              "Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline,week 7,week 20,week 29,week 39,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 29,week 78",
                              "Baseline,week 29,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 52,week 78",
                              "Baseline,week 29,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 78",
                              "Baseline,week 7,week 20,week 29,week 39,week 78",
                              "Basleline,week 29,week 39,week 78",
                              "Baseline,week 39"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04506073"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00976430"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04146519"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in MDS-UPDRS motor (Part III) \"OFF\" score compared to the baseline. All items have 5 response options with uniform anchors of: 0 = normal, 1 = slight (symptoms/signs with sufficiently low frequency or intensity to cause no impact on function), 2 = mild (symptoms/signs of frequency or intensity sufficient to cause a modest impact on function, 3 = moderate (symptoms/signs sufficiently frequent or intense to impact considerably, but not prevent function), 4 = severe (symptoms/signs that prevent function).",
                              "Change in Modified Hoehn & Yahr staging compared to the baseline.",
                              "Degree of radiotracer uptake increment/decrement shown on striatum of 18F-DOPA PET compared to the baseline.",
                              "Reduction of Parkinson's medications consumption by calculating levodopa equivalent daily dose (LEDD) compared to the baseline.",
                              "Change in PDQ-39 scale compared to the baseline. The PDQ-39 is a 39 questions Parkinson's Disease self-completed questionnaire that comprises 8 domains: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items). All items are assumed to impact QoL and must be answered to compute scores for each dimension. Questions are answered based on experiences from the preceding month using a 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each scores range from 0 = never have difficulty to 100 = always have difficulty.",
                              "Net change from baseline in BDI-II scores. BDI-II Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represents a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe). Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression.",
                              "Net change from baseline in HAM-D-17 scores. The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed).",
                              "Net change from baseline in MMSE scores. The MMSE uses a 30 point questionnaire to measure cognitive impairment. The MMSE is scored from 0 to 30,with a score equal to or greater than 24 points indicating normal cognition, a score of 19-23 points indicating mild cognitive impairment, 10-18 points indicating moderate impairment and a score equal to or below 9 indicating severe impairment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale)",
                              "Modified Hoehn & Yahr staging",
                              "18F-DOPA PET",
                              "levodopa equivalent daily dose (LEDD)",
                              "PDQ-39 (Parkinson's Disease Questionnaire)",
                              "Beck Depression Inventory (BDI-II) scores",
                              "Hamilton Depression Rating Scale (HAM-D-17) scores",
                              "Mini Mental State Examination (MMSE) Scores"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at 12, 24, 48 weeks",
                              "at 12, 24, 48 weeks",
                              "at 48 weeks",
                              "at 12, 24, 48 weeks",
                              "at 12, 24, 48 weeks",
                              "at 48 weeks",
                              "at 48 weeks",
                              "at 48 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05094011"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Based on reduction rate, the efficacy can be defined as complete remission, partial remission, effective and invalid. The reduction rate will be 100%, >50%, >25%-50%, \u226425% for complete remission, partial remission, effective and invalid.",
                              "Gait and balance analysis system.",
                              "Blood-based biomarkers will be analysed which include the concentration in ng/ul of \u03b1-synuclein, uric acid, epidermal growth factor, apolipoprotein-A1, and peripheral inflammatory markers using the 20-plex Luminex technology.",
                              "Cerebrospinal Fluid (CSF) based biomarkers such as \u03b1-synuclein (\u03b1Syn), \u03b2-amyloid 1-42 (A\u03b242), tau,phosphorylated tau, and neurofilament light chain will be analyzed and their concentration were measured in ng/ul."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Drug Reduction Rate test",
                              "Tractography",
                              "Blood-based biomarkers",
                              "Cerebrospinal Fluid (CSF) based biomarkers"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03684122"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "MDS-UPDS Parts I, II, III and IV.",
                              "Non-Motor Aspects of Experiences of Daily Living (nM-EDL), including complex behaviors such as, cognitive impairment, hallucinations and psychosis, depressed mood, anxious mood, apathy, features of dopamine dysregulation syndrome, sleep problems, daytime sleepiness, pain and other sensations, urinary problems, constipation problems, light headedness on standing and fatigue.",
                              "Motor Examination, including speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination movements of hands, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, global spontaneity of movement (body bradykinesia), postural tremor of the hands, kinetic tremor of the hands, rest tremor amplitude, constancy of rest tremor, dyskinesias impact and Hoehn and Yahr stage.",
                              "Motor Complications, including time spent with dyskinesias and others.",
                              "Communication - Short Form",
                              "Ability to Participate in Social Roles and Activities - Short Form",
                              "Anxiety - Short Form",
                              "Depression - Short Form",
                              "Emotional and Behavioral Dyscontrol - Short Form",
                              "Fatigue - Short Form",
                              "Lower Extremity Function (Mobility) - Short Form",
                              "Positive Affect and Well-Being - Short Form",
                              "Sleep Disturbance - Short Form",
                              "Upper Extremity Function (Fine Motor, ADL) - Short Form",
                              "Stigma-Short Form",
                              "Satisfaction with Social Roles and Activities - Short Form",
                              "Cognition Function- Short Form",
                              "Score of \u22658 indicates the presence of significant fatigue.",
                              "Difficulties across the 8 quality of life dimensions of functioning of wellbeing.",
                              "Visual Analog Scale for Pain.",
                              "Dosage of medications.",
                              "Adverse Event (TEAEs)",
                              "Including thromboembolic events, peripheral events defined as, thromboembolism of the extremities, also infections and hypersensitivities.",
                              "CBC",
                              "Visual Analog Scale for muscle spasms.",
                              "Changes in Respiratory Rate.",
                              "Changes in Heart Rate.",
                              "Changes in Body Temperature.",
                              "Changes in Blood Pressure.",
                              "Changes in Oxygen Saturation.",
                              "Physical examination results.",
                              "Weight in lb.",
                              "CMP",
                              "Coagulation Panel"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in MDS-UPDS total score.",
                              "Changes in MDS-UPDRS Part I.",
                              "Changes in MDS-UPDRS Part III.",
                              "Changes in MDS-UPDRS Part IV.",
                              "Changes in Neuro-QOL. - Communication",
                              "Changes in Neuro-QOL. - Social Roles and Activities",
                              "Changes in Neuro-QOL. - Anxiety",
                              "Changes in Neuro-QOL. - Depression",
                              "Changes in Neuro-QOL. - Dyscontrol",
                              "Changes in Neuro-QOL. - Fatigue",
                              "Changes in Neuro-QOL. - Mobility",
                              "Changes in Neuro-QOL. - Well-Being",
                              "Changes in Neuro-QOL. - Sleep",
                              "Changes in Neuro-QOL. - Fine Motor",
                              "Changes in Neuro-QOL. - Stigma",
                              "Changes in Neuro-QOL. - Social Roles",
                              "Changes in Neuro-QOL. - Cognition",
                              "Changes in Parkinson's disease fatigue scale (PFS-16).",
                              "Changes in Parkinson's disease Questionnaire (PDQ-39).",
                              "Changes in Visual Analog Scale for Pain.",
                              "Changes in Dosage of medications taken to treat Parkinson's disease.",
                              "Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).",
                              "Incidence and risk of AEs of special interest (serious or non-serious),",
                              "Clinically significant changes in laboratory values. - CBC",
                              "Changes in Visual Analog Scale for muscle spasms.",
                              "Clinically significant changes in vital signs. - Respiratory Rate",
                              "Clinically significant changes in vital signs. - Heart Rate",
                              "Clinically significant changes in vital signs. - Body Temperature.",
                              "Clinically significant changes in vital signs. - Blood Pressure.",
                              "Clinically significant changes in vital signs. - Oxygen Saturation.",
                              "Clinically significant changes in physical examination results.",
                              "Clinically significant changes in weight in lb.",
                              "Clinically significant changes in laboratory values. - CMP",
                              "Clinically significant changes in laboratory values. - Coagulation Panel"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04928287"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in MDS-UPDRS Part I",
                              "Changes in Total score MDS-UPDRS Part II and Part III",
                              "Changes in MDS-UPDRS Part III",
                              "Changes in MDS-UPDRS Part IV",
                              "Changes in SF-36",
                              "Improvements in Participants PFS-16 scores",
                              "Improvements in Participants PDQ-39 scores",
                              "Changes in Participants VAS Pain Scales",
                              "Changes in Participants VAS spasms Scale",
                              "Changes in Participants medications taken"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.",
                              "19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.",
                              "20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.",
                              "21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.",
                              "22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).",
                              "23. Changes in Parkinson's disease fatigue scale (PFS-16)",
                              "24. Changes in Parkinson's disease Questionnaire (PDQ-39).",
                              "25. Changes in Visual Analog Scale for Pain.",
                              "26. Changes in Visual Analog Scale for Muscle spasms.",
                              "27. Changes in Dosage of medications taken to treat Parkinson's disease."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04995081"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Hope Biosciences Stem Cell Research Foundation"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.hopebio.org/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04772378"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04876326"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2011-004051-39"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "change vs baseline in the striatal density of dopamine transporters in SPECT brain images and in the normalized regional cerebral flow / glucose metabolism in the gray matter in PET brain images after one year"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "changes in brain images"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "one year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01824121"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04514952"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The Barthel Index measures 10 activities of daily living and mobility. A score of 100 is best (able to live at home with a degree of independence), 0 is worst.",
                              "The Mini-Mental State Examination (MMSE) is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.",
                              "The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.",
                              "The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.",
                              "adverse reaction include temperature changes,the change of blood pressure,anaphylaxis,seizure,renal dysfunction,or hepatic injury by monitoring blood routine, urinalysis, ALT,AST,Urea,Crea and electrocardiogram etc."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The Barthel Index",
                              "The Mini-Mental State Examination (MMSE)",
                              "The Montreal Cognitive Assessment(MoCA)",
                              "Unified Parkinson's Disease Rating Scale (UPDRS)",
                              "adverse reaction"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "before treatment and post cell transplantation:15,90,180 days",
                              "before treatment and post cell transplantation:15,90,180 days",
                              "before treatment and post cell transplantation:15,90,180 days",
                              "before treatment and post cell transplantation:15,90,180 days.",
                              "post cell transplantation:15,90,180 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01962233"
                        ]
                  }
            ]
      }
}